Discover the reality of companies and brands!
Free and independant information on large corporations


Headquarters : Five Giralda Farms Madison, NJ 07940 United States of America United States of America web tel. 973-660-5000 stock : WYE analytics


click to compare prices
» Shop local, ethical and at the best price on Ethishop

« Ethical » rating of Wyeth , group Pfizer, Inc. and subsidiaries

Human 1 Jobs -16% /1998 Pollution 10 Fraud 8 Offshore 16 Sales 48 Bn $.€ /year Profit 86 Bn $.€ /1998 Wage 2167 *min. Influence 27 Infocom 13
[click on the rating for the method or on the number for the data]

Pfizer, Inc.United States of America100Cercle Finance
» More shareholders of Wyeth
2006Wyeth is the world's eleventh-largest pharmaceutical group.Les Echos
2006Wyeth sells 16% of the vaccines bought in the world.Les Echos
Cyanamid United States of America100
Fort Dodge United States of America100
Genetics Institute United States of America100
Whitehall Robins United States of America100
Wyeth-Ayerst United States of America100
» More subsidiaries of Wyeth
address & contact : production type
incentive source
Ireland Ireland
Newbridge : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Ireland Ireland
Limerick : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Ireland Ireland
AHP Finance Ireland Ltd., Dublin :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Switzerland Switzerland
Dimminaco AG :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)

  • Human impact

year name
photo position; compensation
2002Essner, Robert
See the photo of: Essner, Robert Chief Executive Officer; salary: 3,13 million US$; stock-options: 3,64 million US$;
2002Martin, Kenneth
See the photo of: Martin, Kenneth Chief Financial Officer; salary: 1,64 million US$; stock-options: 0,24 million US$;
1999Alexander, Clifford L
See the photo of: Alexander, Clifford L Director;
1999Bennack, Franck A
See the photo of: Bennack, Franck A Director;
1999Essner, Robert
See the photo of: Essner, Robert Director;
1999Feerick, John D
See the photo of: Feerick, John D Director;
1999Mascotte, John P
See the photo of: Mascotte, John P Director;
1999Polan, Mary Lake
See the photo of: Polan, Mary Lake Director;
1999Torell, John R
See the photo of: Torell, John R Director;
1999Van G Seidenberg, I
See the photo of: Van G Seidenberg, I Director;
1998Stafford, John R
See the photo of: Stafford, John R Chief Executive Officer; salary: 21,34 million US$;
social impact : country
Internal restructuring: Wyeth told managers about 10 percent of its 50,000 employees worldwide might lose their jobs by 2011 under a sweeping reorganization dubbed "Project Impact.": United States of America
Closure/Bankruptcy: United States of America
Les Echos
country : consequences
2007United States of America : Wyeth was condemned to pay 134 million dollars to three patients who developed a breast cancer because of their hormonal treatment Premanal and Prempro.Les Echos
2005United States of America : Wyeth a versé 14 milliards de dollars aux patients qui ont pris son coupe-faim Redux, retiré du marché en 1997. Wyeth a provisionné 7 milliards de plus pour les paiements futurs.Les Echos

  • Subsidy

yearfinancial misdemeanorsalesincome source
2005 Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said.     Canadian Press
2004   1,23   billion US$Les Echos
2002   14,584,45   billion US$
2002 Pratiques fiscales douteuses, déclarations mensongères aux auditeurs, utilisation frauduleuse des budgets marketing, inventaires gonflés, contrats avec des sociétés liées à certains dirigeants, primes déposées dans des comptes offshore…     New York Times
2001   14,132,29   billion US$
2000   13,26-2,37   billion US$
1999   13,55-1,23   billion US$
1998   13,462,47   billion US$
yearfinancial misdemeanorsalesincomeassetsbuybacksource
 8 informations, access to subscribers
purpose : intermediary/lobby : institution
2001Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government translateUSCIB
2000Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translateWashington Post
2000Investment protection and market access (to Mexico and Canada through NAFTA), to Latin America (through FTAA). : Business Roundtable : : US government, senate, congress translateCenter for Responsive Politics
1998Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 52 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
1997Legislation favorable to company's interests : Direct donation : amount: 103 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
1997Legislation favorable to company's interests : Direct donation : amount: 2500 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
purpose : intermediary/lobby : institution
 6 informations, access to subscribers
dubious practice : image
2008Disinformation: According to internal documents, the pharmaceutical company Wyeth "paid ghostwriters to produce medical journal articles favorable to its female hormone replacement therapy Prempro." As early as 1997, Wyeth paid the "medical writing firm" DesignWrite to publish favorable journal articles about Prempro under academics' names. "Company executives came up with ideas" for the articles, "titled them, drafted outlines, paid writers to draft the manuscripts, recruited academic authors and identified publications to run the articles -- all without disclosing the companies' roles to journal editors or readers.: New York Times
2007Disinformation: In early September, "major newspapers reported the alarming news that suicides among young people were on the rise because of a precipitous drop in the use of antidepressants," writes Alison Bass. The academic study the news articles were based on concluded that new safety warnings for young people using antidepressant drugs had discouraged doctors from writing prescriptions for depressed youths. But there's a hole in that argument: "while there was indeed an upturn in suicide rates among youths ... the number of prescriptions for antidepressants in the same age group remained basically unchanged." Bass points out that the pharmaceutical companies that make antidepressants might "benefit from the latest alarm about an apparent upturn in youth suicide rates. ... These companies have an enormous stake in reversing the current FDA warnings." Pfizer, which makes the antidepressant Zoloft, did provide $30,000 for the academic study, and the study's lead authors have ties to Pfizer, GlaxoSmithKline and Wyeth Pharmaceuticals. "This isn't the first time that suicide rates have been trotted out as a public relations weapon," Bass adds. "Proponents of psychotropic drugs have long argued that suicide rates ... fell after" such drugs were introduced, though the decline began well before the drugs were widely prescribed.: Boston Globe
2001ad budget: 400 million US$; Advertising Age
2000ad budget: 445 million US$; Advertising Age
1998ad budget: 428 million US$; Advertising Age
1997ad budget: 443 million US$; Advertising Age

Bookmark and Share    en español  en français  in italiano
translate this page in arabic chinese dutch german japanese korean russian
Legal notice © T&C 1999-2010